



## Frontiers in Digestive Research and Practice

<b>Name</b>	Yao-Chun (Holden) Hsu
<b>Affiliation</b>	E-Da Hospital, I-Shou University
<b>Country</b>	Taiwan
<b>Major Field</b>	Chronic hepatitis B

### Educational Background

1996-2002: MD, School of Medicine, National Taiwan University, Taiwan  
 2007-2009: MSc, Graduate Institute of Clinical Medicine, National Taiwan University, Taiwan  
 2011-2014: PhD, Graduate Institute of Clinical Medicine, China Medical University, Taiwan

### Professional Experience

2018-present, Associate Editor (Liver section), Digestive Diseases  
 2023-present, Editorial Board, Clinical and Molecular Hepatology  
 2024-present, International Editorial Board, Alimentary Pharmacology & Therapeutics

### Main Scientific Publications

- Hsu YC**, Chen CY, Tseng CH, Chen CC, Lee TY, Bair MJ, Chen JJ, Huang YT, Chang IW, Chang CY, Wu CY, Wu MS, Mo LR, Lin JT. Antiviral Therapy for Chronic Hepatitis B with Mildly Elevated Aminotransferase: A Rollover Study from the TORCH-B Trial. *Clin Mol Hepatol*. 2024 [in press].
- Pan DZ, Soulette CM, Aggarwal A, Han D, van Buuren N, Wu P, Feierbach B, Lin JT, Tseng CH, Chen CY, Downie B, Mo H, Diehl L, Li L, Fletcher SP, Balsitis S, Ramirez R, Suri V, **Hsu YC\***. Effects of Tenofovir Disoproxil Fumarate on Intrahepatic Viral Burden and Liver Immune Microenvironment in Patients with Chronic Hepatitis B. *Gut* 2024 [in press].
- Tsai YN, Wu JL, Tseng CH, Chen TH, Wu YL, Chen CC, Fang YJ, Yang TH, Nguyen MH, Lin JT, **Hsu YC\***. Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation. *Clin Mol Hepatol*. 2024 Jan;30(1):98-108.
- Hsu YC**, Lin YH, Lee TY, Nguyen MH, Tseng CH, Ho HJ, Kao FY, Lin JT, Wu CY, Wu CY. Severe hepatitis B flares with hepatic decompensation after withdrawal of nucleos(t)ide analogues: A population-based cohort study. *Aliment Pharmacol Ther*. 2023;58(4):463-473.
- Hsu YC\***, Huang DQ, Nguyen MH\*. Global burden of hepatitis B virus: current status, missed opportunities and a call for action. *Nat Rev Gastroenterol Hepatol*. 2023 Aug;20(8):524-537.
- Hsu YC**, Tseng CH, Kao JH\*. Safety Considerations for Withdrawal of Nucleos(t)ide Analogues in Patients with Chronic Hepatitis B: First, Do No Harm. *Clin Mol Hepatol*. 2023 Oct;29(4):869-890.
- Hsu YC**, Suri V, Nguyen MH, Huang YT, Chen CY, Chang IW, Tseng CH, Tseng, Wu CY, Lin JT, Pan DZ, Gaggar A, Podlaha O\*. Inhibition of Viral Replication Reduces Transcriptionally Active Distinct Hepatitis B Virus Integrations with Implications on Host Gene Dysregulation. *Gastroenterology*. 2022;162(4): 1160-1170.
- Hsu YC\***, Wu JL, Tseng CH, Nguyen MH, Lin CW, Hung CL. Severe Acute Exacerbation After Cessation of Nucleos(t)ide Analog for Chronic Hepatitis B: A Real-World Study of Routine Practice. *Clin Gastroenterol Hepatol*. 2022;20(6): 1413-1415.
- Hsu YC**, Chen CY, Chang IW, Chang CY, Wu CY, Lee TY, Wu MS, Bair MJ, Chen JJ, Chen CC, Tseng CH, Tai CM, Huang YT, Ku WH, Mo LR, Lin JT\*. Tenofovir for Chronic Hepatitis B in Treatment-naïve Asian Patients with Minimally Raised Aminotransferase (TORCH-B): a multicenter randomized double-blind placebo-controlled trial. *Lancet Infect Dis*. 2021; 21(6):823-833
- Tseng CH†, **Hsu YC† (co-first)**, Chen ZH, Ji F, Chen IS, Tsai YN, Hai H, Thuy LTT, Hosaka T, Sezaki H, Borghi JA, Cheung R, Enomoto M, Nguyen MH\*. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol*. 2020Dec; 5(12):1039-1052.